Quotient Limited (QTNT) Upgraded by Zacks Investment Research to Hold
Zacks Investment Research upgraded shares of Quotient Limited (NASDAQ:QTNT) from a sell rating to a hold rating in a report issued on Wednesday morning.
According to Zacks, “Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania. “
Several other brokerages have also recently issued reports on QTNT. BTIG Research reaffirmed a buy rating and set a $12.00 price objective on shares of Quotient Limited in a report on Thursday, August 31st. ValuEngine raised Quotient Limited from a strong sell rating to a sell rating in a report on Friday, June 30th.
Quotient Limited (NASDAQ:QTNT) last issued its quarterly earnings data on Monday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.55). The business had revenue of $6.83 million for the quarter, compared to analysts’ expectations of $5.70 million. Quotient Limited had a negative return on equity of 13,050.41% and a negative net margin of 381.66%.
COPYRIGHT VIOLATION WARNING: This story was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/quotient-limited-qtnt-upgraded-by-zacks-investment-research-to-hold/1578420.html.
In other news, insider D J. Paul E. Cowan sold 9,420 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $6.11, for a total transaction of $57,556.20. Following the sale, the insider now directly owns 26,666 shares of the company’s stock, valued at approximately $162,929.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider D J. Paul E. Cowan sold 45,032 shares of the company’s stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $6.57, for a total value of $295,860.24. Following the sale, the insider now directly owns 26,666 shares in the company, valued at $175,195.62. The disclosure for this sale can be found here. Insiders have sold a total of 365,612 shares of company stock worth $1,884,079 over the last ninety days. Insiders own 29.00% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of QTNT. California State Teachers Retirement System purchased a new stake in Quotient Limited during the 2nd quarter valued at $349,000. The Manufacturers Life Insurance Company purchased a new stake in Quotient Limited during the 2nd quarter valued at $177,000. Scholtz & Company LLC purchased a new stake in Quotient Limited during the 2nd quarter valued at $939,000. State Street Corp purchased a new stake in Quotient Limited during the 2nd quarter valued at $1,728,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Quotient Limited during the 2nd quarter valued at $104,000. 57.68% of the stock is currently owned by institutional investors and hedge funds.
Quotient Limited Company Profile
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
Receive News & Ratings for Quotient Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.